Avita Medical, Inc. is a regenerative medicine company that develops and commercializes innovative technologies to treat acute and chronic wounds. The company’s flagship product, the ReCell® System, is a point-of-care medical device that enables clinicians to process a small sample of a patient’s skin into a suspension of autologous cells for application to areas of skin damage. By harnessing the body’s natural regenerative capacity, Avita Medical aims to provide improved clinical outcomes in the management of burns, donor site wounds and other soft tissue injuries.
The ReCell® System employs a proprietary enzymatic and mechanical process to isolate viable skin cells—keratinocytes, melanocytes and fibroblasts—from a minimal donor site sample. This approach reduces the need for extensive skin harvesting, limits donor site morbidity and accelerates the wound-healing process. Avita Medical’s product portfolio also includes complementary accessories designed to support consistent preparation and delivery of the cell suspension in surgical and burn care settings.
Headquartered in Carlsbad, California, with additional operations in Australia and strategic distributors in Europe and select markets in Asia, Avita Medical serves a global network of burn centers, hospitals and specialized clinics. The company collaborates closely with key opinion leaders and participates in clinical trials to expand the evidence base supporting its technology, while maintaining regulatory clearances in the United States, Europe, Australia and other jurisdictions.
Founded in 1997 and formerly known as Clinical Cell Culture, Avita Medical has evolved under a management team with deep expertise in medical device development, clinical research and biomanufacturing. Guided by a board of directors and senior executives drawn from the biotechnology and healthcare sectors, the company continues to invest in innovation aimed at improving patient care and reducing the overall burden of wound treatment.
AI Generated. May Contain Errors.
